All News
Combo Therapy Boosts Response in Uncontrolled Gout
The addition of an immunomodulating agent to pegloticase (Krystexxa) among patients with uncontrolled gout significantly improved response rates, a systematic literature review found.
Read ArticleNEJM: Interleukin-6 Inhibition in Critically-Ill COVID-19
The pendulum and jury are wavering with regard to the benefits of interleukin-6 receptor antagonists in COVID-19; the current NEJM reports the results of a study favoring such biologic therapy in in critically ill COVID-19 patients.
Read Article
Links:
Dr. John Cush RheumNow ( View Tweet)

Links:

Links:
Dr. John Cush RheumNow ( View Tweet)

Links:

Links:

Links:

Links:
Dr. John Cush RheumNow ( View Tweet)

Links:

Links:

Links:
Dr. John Cush RheumNow ( View Tweet)

QD Clinic: PFAPA Syndrome Recurrent Fevers, Stomatitis, Lymphadenopathy ? https://t.co/uMBk8e2wJO https://t.co/02ZMjRmOuU
Links:

Links:
Dr. John Cush RheumNow ( View Tweet)

Links:
Dr. John Cush RheumNow ( View Tweet)

Links:
Dr. John Cush RheumNow ( View Tweet)

Links:
Dr. John Cush RheumNow ( View Tweet)

Links:
Dr. John Cush RheumNow ( View Tweet)

Links:
Dr. John Cush RheumNow ( View Tweet)

Links:
Dr. John Cush RheumNow ( View Tweet)